



PRESS RELEASE

## Successful financing round for pharmaceutical company AMW

- *Funding will be targeted on innovative technology for controlled drug delivery using transdermal patch systems*
- *Basis for marketing and sales efforts will be broadened*

**Warngau, September 8, 2014 – AMW GmbH (Arzneimittelwerk Warngau) has secured follow-up financing to advance the development and marketing process for its drug delivery systems. BayBG Bayerische Beteiligungsgesellschaft, UnternehmerTUM Fund and IBG Beteiligungsgesellschaft are joining existing investors to inject up to seven million euro. The new funds will be used to market the existing product portfolio and develop a new technology for controlled drug delivery. AMW GmbH produces active ingredient implants and transdermal systems in the high-growth areas of oncology, pain therapy and neurology.**

The current round of financing is intended to initially increase AMW GmbH's capital by five million euro. Existing shareholders including the anchor investor SHS Gesellschaft für Beteiligungsmanagement, Bayern Kapital, KfW and AMW's Managing Director Wilfried Fischer have together invested 1.4 million euro in the company. In a second closing, the three new shareholders IBG Beteiligungsgesellschaft Sachsen-Anhalt with its "Risikokapitalfonds II" fund, the UnternehmerTUM Fund and BayBG Bayerische Beteiligungsgesellschaft have together provided 3.6 million euro. "This round of financing puts us in the position to bolster our marketing activities and submit our controllable transdermal technology for approval", comments Dr. Wilfried Fischer on the capital contribution. SHS Managing Director Bernhard Schirmers adds: "AMW as a company has now entered a phase in which focus can be placed on marketing its promising product range. We are taking a major step into the market with the funds from this round of financing."

Since its inception in 2008, AMW has evolved into a successful company with GMP production. The Warngau based company specializes in drug delivery systems – a very attractive segment of the pharmaceutical market, which is experiencing rapid growth around the globe. These systems deliver medication to patients using transdermal patches or subcutaneous implants. In addition to improved efficacy and tolerability, these systems provide simplified handling and dosing of medications. Since its inception, AMW has developed an attractive product portfolio in the areas of oncology and neurology. One product has already received approval, three products are in the approval process, and three other products are in the final stages of clinical development. AMW intends to use the funds from this financing round to develop an active transdermal technology, which in contrast to today's passive technology can be used to release drugs in a controlled manner adapted to the needs of the individual patients.

BayBG investment manager Otto Hopfner lists further reasons for the investment: "The demand for patch and implant systems is experiencing dynamic growth for several years now and the segment currently amounts to approximately 30 billion US dollars. AMW is superbly positioned in this growth market and boasts numerous innovations."

"We are impressed by the long-term track record and extensive process know-how of Dr. Wilfried Fischer and his team", says Timo Komulainen, Managing Partner of the UnternehmerTUM Fund. "We will be actively supporting the planned setup of international sales for the new products", Komulainen adds.

"We see a great medical need for drug implants and transdermal systems and a wide range of benefits especially in the areas of oncology, pain therapy and neurology", explains Martin Laub, Investment Manager at IBG, and adds, "With both its existing product portfolio and the new technologies to be developed, AMW as a whole is in an excellent position to implement its targeted growth strategy."

Endomedica GmbH, a 100% subsidiary of AMW headquartered in Halle (Saale), will take on an essential role in this regard in the future. In addition to marketing its own existing product portfolio, it will be responsible for driving and coordinating the technical and clinical development of innovative, controllable transdermal technologies in partnership with scientific institutions in the region.

#### **About AMW GmbH**

AMW GmbH is a pharmaceuticals company, which specializes in innovative drug delivery systems. AMW's products deliver medication to patients using transdermal patches or subcutaneous implants. The company was established by Dr. Wilfried Fischer in 2008 and develops treatment solutions in the areas of oncology, neurology, dermatology and pain therapy. AMW is located in Warngau in the Upper Bavaria region of Germany.

#### **About BayBG:**

Through its investments, BayBG is currently strengthening the capital base of 500 Bavarian medium-sized businesses. The BayBG is thus the Bavarian market leader among medium-sized enterprise-oriented investment companies. Through its commitment, the BayBG enables the companies to realize expansion and innovation plans, make corporate succession plans as well as optimize the capital structure and implement of turn-around measures.

#### **About UnternehmerTUM Fund**

UnternehmerTUM Fund provides venture capital for young high technology companies in the industry sectors Information and Communication Technologies (ICT), Medical Engineering and CleanTech. UnternehmerTUM Fund offers to the portfolio companies a wealth of experience in strategic and operative business development and a unique network encompassing industry partners and other venture capital investors.

#### **EIF, ERP and CIP:**

UnternehmerTUM Fund is partially funded by the European Investment Fund (EIF), by the European Union, through the Competitiveness and Innovation Framework Programme (CIP), as well as by the ERP-EIF Dachfonds and the LfA-EIF Dachfonds.



### **About IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH:**

The IBG Beteiligungsgesellschaft Saxony-Anhalt mbH, based in Magdeburg, manages the three investment funds IBG Risikokapitalfonds I GmbH & Co. KG, IBG Risikokapitalfonds II GmbH & Co. KG and the IBG Innovationsfonds GmbH & Co. KG. The funds invest primarily in technology-based startup companies in Saxony-Anhalt. Investments are preferably made in the fields of technology, life science, new materials, new energy, microsystems technology, software engineering and process engineering / mechanical engineering.



### **More information:**

Dr. Reinhard Saller  
IRA WÜLFING KOMMUNIKATION GmbH  
t: +49.(0)89. 2000 30-38  
[reinhard.saller@wuefling-kommunikation.de](mailto:reinhard.saller@wuefling-kommunikation.de)